The IGF1R Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout population in which the human IGF1R gene has been disrupted, eliminating functional insulin-like growth factor 1 receptor (IGF1R) expression. This cell tool is generated from the 143B osteosarcoma cell line and provides a heterogeneous loss-of-function model for investigating IGF1R-dependent signaling in a bone cancer context. The polyclonal nature preserves the diverse mutational landscape of the original cell line, making it suitable for pooled screening and bulk biochemical assays.
The 143B cell line is a widely used human osteosarcoma model derived from a malignant bone tumor. It exhibits adherent growth and retains key features of osteosarcoma biology, including aggressive proliferation and metastatic potential. This cell line serves as a standard platform for studying bone cancer pathogenesis, drug response, and tumor microenvironment interactions. The 143B background is particularly relevant for exploring growth factor receptor pathways implicated in osteosarcoma survival and progression.
IGF1R is a transmembrane receptor tyrosine kinase that is activated by its ligands IGF1, IGF2, and insulin, as well as by growth hormone. Upon ligand binding, IGF1R recruits adaptor proteins such as IRS1 and SHC, leading to activation of the PI3K/AKT and MAPK/ERK signaling cascades. Downstream, AKT phosphorylates multiple targets including FOXO transcription factors, while ERK1/2 regulates the expression of cell cycle components like Cyclin D1 and anti-apoptotic BCL2. IGF1R signaling is also modulated by interacting partners including GRB2, SOS, and the phosphatase PTEN, ensuring tight control over cell growth and metabolism. In this knockout model, disruption of IGF1R abrogates ligand-dependent activation of both IRS1-mediated PI3K/AKT/mTOR and SHC-mediated RAS/RAF/MEK/ERK pathways, resulting in diminished proliferative and survival signals.
In the 143B osteosarcoma context, IGF1R plays a pivotal role in sustaining malignant phenotypes. Loss of IGF1R in these polyclonal knockout cells leads to attenuated downstream signaling, which correlates with reduced cell proliferation and enhanced apoptosis. This model is particularly advantageous for dissecting the contribution of IGF1R to osteosarcoma tumorigenesis, as it avoids confounding effects from clonal selection. Researchers can utilize this cell population to study how IGF1R deficiency impacts anchorage-independent growth, cytoskeletal organization, and sensitivity to chemotherapeutic agents. Furthermore, the presence of a mixed genetic background allows evaluation of pathway addiction heterogeneity within the tumor cell population.
The IGF1R Knockout 143B Polyclonal Cells are suitable for a broad range of experimental applications. They can be employed in phospho-signaling profiling by Western blotting and phospho-specific antibody arrays to map acute changes in AKT, ERK, and mTOR phosphorylation. RT-qPCR and RNA sequencing can be used to assess transcriptional alterations in FOXO targets and cell cycle regulators. Functional assays such as cell proliferation, apoptosis, and migration assays enable quantitative assessment of IGF1R-dependent phenotypes. Additionally, this knockout model supports drug sensitivity testing against IGF1R inhibitors and other targeted therapies, aiding in the identification of resistance mechanisms. The cells are also valuable for co-culture studies to explore the role of IGF1R in the bone tumor microenvironment. For further information, please contact Ascent Research.
